Developer docs
API playgroundTry for free, no card

Search company profiles

LongeVC

Full company profile

uuid0000w6j

Namestring
LongeVC
Legal namestring
LongeVC
Websiteurl
longevc.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

LongeVC is a privately-held, Washington D.C.-headquartered venture capital firm founded in 2020 that invests in early-stage biotechnology and longevity-focused companies. The firm deploys capital across three explicit pillars — Therapeutics (pre-clinical and clinical drug development targeting molecular and cellular mechanisms of aging), Diagnostics & Prevention (personalized medicine and advanced diagnostics), and Longevity Infrastructure (platform technologies for faster drug discovery and testing) — and currently operates two funds (Fund I and Fund II) supporting 40+ portfolio companies. Its investment activity is concentrated in named holdings such as Insilico Medicine (AI drug discovery), Rubedo Life Sciences (senolytics), Turn.bio (mRNA medicines), Trogenix (precision oncology, $95M Series A in October 2025), Valink Therapeutics (bsADCs), and Constructive Bio (engineered protein therapeutics), among others.

LongeVC monetizes as a traditional early-stage VC, generating returns through equity stakes in portfolio companies with future liquidity via IPOs, acquisitions, or secondaries; the firm has no disclosed management fees, AUM, or limited partner structure. Beyond capital, the firm offers a curated ecosystem of support: a paid 6-month Venture Fellowship Program (now in its third cohort) that sources graduate-student talent and evaluates potential investments alongside the investment team; an advisory board of scientific luminaries including 2013 Nobel Laureate Michael Levitt, NAS members Vadim Gladyshev and Thomas Rando, longevity researcher Matt Kaeberlein, and AI-bio pioneer Alex Zhavoronkov; and a wholly-owned operating subsidiary, Founders Search Advisors (FSA), launched November 2025 to recruit executive talent for portfolio companies using equity-based compensation. The operating team spans three Managing Partners (Ilya Suharenko, Garri Zmudze, Sergey Jakimov) and additional Partners, Venture Partners, Principals, and a COO and CFO. Distribution and deal sourcing run through direct advisor/fellow networks, the 'Through the Longevity Lens' Substack newsletter, LinkedIn/X channels, industry events, and partnerships with sector bodies such as the Longevity Science Foundation and the Longevity Biotech Association.

Short descriptiontext

LongeVC is an early-stage venture capital firm headquartered in Washington D.C. that deploys Fund I and Fund II capital across therapeutics, diagnostics, and longevity infrastructure, supporting 40-plus portfolio biotech and longevity companies globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWashington, United States
HQ citystring
Washington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital, biotech investing, longevity investing, early-stage investment, healthcare venture capital
Industry1 code
PRIMARYFSANAAAC
Late-Stage Venture Capital (Series C+)
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns / Carry
TypeLicensing Royalties
Description

As a venture capital firm, LongeVC generates returns through equity investments in early-stage biotech companies. Returns come from portfolio company exits via IPOs, acquisitions, or secondary sales. The firm manages Fund I and Fund II, investing across therapeutics, diagnostics and prevention, and longevity infrastructure.

longevc.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Founders Search Advisors (FSA)
Description

Executive search firm launched by LongeVC to assist longevity biotech startups in recruiting top talent using equity-based compensation model

longevity.technology
Core offering1 text field

LongeVC is an early-stage venture capital firm that deploys capital into biotech and longevity-focused companies through Fund I and Fund II, with focused investment pillars in Therapeutics, Diagnostics & Prevention, and Longevity Infrastructure. The firm curates an ecosystem of more than 40 portfolio companies and provides strategic guidance, talent acquisition support, and connections to a global network of thought leaders. Complementary offerings include a 6-month paid Venture Fellowship Program and the Founders Search Advisors executive search firm launched in November 2025.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Portfolio companies include industry leaders such as Insilico Medicine (AI drug discovery unicorn), Rubedo Life Sciences (senolytics), Turn.bio (mRNA medicines), and The Longevity Science Foundation (non-profit research funding)
Product overview1 text field

LongeVC is a venture capital platform operating as a single, unified investment offering rather than a modular software product. The firm provides venture capital investment services alongside complementary programs including a Venture Fellowship Program for talent development and Founders Search Advisors for executive recruiting. The core investment focus spans three verticals: Therapeutics (pre-clinical and clinical drug development targeting aging mechanisms), Diagnostics & Prevention (early-stage personalized medicine and advanced diagnostics), and Longevity Infrastructure (platform technologies enabling faster drug discovery and testing at scale).

Product and service3 records
1LongeVC Investment Platform (Fund I and Fund II)
CategoryVenture Capital Investment
Description

Early-stage venture capital investment platform operated through Fund I and Fund II that invests in exceptional biotech and longevity-focused founders developing therapeutics, diagnostics & prevention, and longevity infrastructure, providing capital alongside ecosystem connections to drive portfolio company advancement.

2Venture Fellowship Program
CategoryTalent Development Program
Description

A 6-month, part-time, remote paid fellowship program for graduate students (MS/PhD) and postdoctoral fellows that provides paid exposure to biotech venture investing, including evaluating potential investments, participating in company pitches, and developing strategic initiatives in drug discovery, computational and synthetic biology, and genomic medicine.

3Founders Search Advisors (FSA)
CategoryExecutive Search Services
Description

Executive search firm launched by LongeVC to assist longevity biotech startups in recruiting top talent using an equity-based compensation model, addressing funding and talent acquisition challenges faced by early-stage longevity biotech companies.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Founders Search Advisors (FSA)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-06
Description

Founders Search Advisors (FSA) is an executive search firm launched by LongeVC to assist longevity biotech startups in recruiting top talent using an equity-based compensation model. The firm addresses funding and talent acquisition challenges faced by early-stage longevity companies.

longevity.technology
2The Longevity Science Foundation
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The Longevity Science Foundation is an international non-profit funding early-stage research on extending healthy human lifespan. LongeVC is connected to LSF through shared leadership (Alex Zhavoronkov serves on LSF's Visionary Board) and supports LSF's mission through investment and ecosystem building. LSF has launched campaigns such as the 'Invested in Her' crowdfunding for ovarian aging research.

longevc.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The Longevity Biotech Association is a portfolio organization and consortium aiming to advance the longevity industry by setting standards, educating stakeholders, and encouraging partnerships.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

a16z Bio is the dedicated healthcare and biology investment arm of Andreessen Horowitz, investing in bio companies at the intersection of technology and life sciences. Comparable to LongeVC because of shared interest in AI-driven drug discovery and platform biotech, though a16z Bio operates with far greater resources.

TypeBroad incumbent
Description

8VC is a multi-stage venture firm with bio and longevity exposure alongside its broader tech portfolio. Comparable to LongeVC as an early-stage investor in biotech and life-sciences platforms, though 8VC operates across many technology categories beyond longevity.

TypeRegional player
Description

Longevity Vision Fund is a Russia-origin venture fund focused on longevity, biotech, and preventive medicine. Comparable to LongeVC as another dedicated longevity-focused VC, though it serves a different geographic ecosystem and overlaps with LongeVC in shared thesis on aging biology.

TypeBroad incumbent
Description

Khosla Ventures invests broadly across technology and biotech, including longevity-adjacent therapeutics and diagnostics. Comparable to LongeVC because both deploy early-stage capital into high-impact science, but Khosla operates at much greater AUM scale and across many sectors beyond biotech.

TypeDirect peer
Description

DCVC Bio is the dedicated bio and life sciences arm of DCVC, investing in early-stage biotech companies using computational and engineering approaches. Comparable to LongeVC because both target deep-tech biotech at the early stage and share an AI/bio convergence thesis.

TypeDirect peer
Description

Foresite Capital is a dedicated healthcare and biotech venture firm investing across therapeutics, diagnostics, and healthcare infrastructure. Comparable to LongeVC because both deploy capital into science-driven biotech and longevity infrastructure at the early stage.

TypeBroad incumbent
Description

ARCH Venture Partners is one of the largest dedicated biotech and advanced-technology venture firms, with deep exposure to longevity-relevant platforms. Comparable to LongeVC as a science-led biotech investor with Nobel-caliber scientific advisors, but at a substantially larger fund scale.

TypeBroad incumbent
Description

Founders Fund invests across frontier technology sectors including biotech and longevity-adjacent companies. Comparable to LongeVC because both back bold science bets, but Founders Fund is a generalist tech investor with massive fund sizes compared to LongeVC's niche focus.

TypeDirect peer
Description

Section 32 is a venture capital firm that invests in biotech, healthtech, and technology platforms with a science-grounded approach. Directly comparable to LongeVC because both invest early in biotech and aim to back technical founders, though Section 32 is broader in scope beyond longevity.

TypeDirect peer
Description

Apollo Ventures is a dedicated early-stage venture capital firm focused exclusively on longevity and age-related disease therapeutics. Highly comparable to LongeVC because it competes for the same small pool of longevity-focused biotech founders and shares a similar thesis-driven, science-led investment approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles28 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment23 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LongeVC

Venture Capitallongevc.com

LongeVC is an early-stage venture capital firm headquartered in Washington D.C. that deploys Fund I and Fund II capital across therapeutics, diagnostics, and longevity infrastructure, supporting 40-plus portfolio biotech and longevity companies globally.

What LongeVC does

LongeVC is a privately-held, Washington D.C.-headquartered venture capital firm founded in 2020 that invests in early-stage biotechnology and longevity-focused companies. The firm deploys capital across three explicit pillars — Therapeutics (pre-clinical and clinical drug development targeting molecular and cellular mechanisms of aging), Diagnostics & Prevention (personalized medicine and advanced diagnostics), and Longevity Infrastructure (platform technologies for faster drug discovery and testing) — and currently operates two funds (Fund I and Fund II) supporting 40+ portfolio companies. Its investment activity is concentrated in named holdings such as Insilico Medicine (AI drug discovery), Rubedo Life Sciences (senolytics), Turn.bio (mRNA medicines), Trogenix (precision oncology, $95M Series A in October 2025), Valink Therapeutics (bsADCs), and Constructive Bio (engineered protein therapeutics), among others.

LongeVC monetizes as a traditional early-stage VC, generating returns through equity stakes in portfolio companies with future liquidity via IPOs, acquisitions, or secondaries; the firm has no disclosed management fees, AUM, or limited partner structure. Beyond capital, the firm offers a curated ecosystem of support: a paid 6-month Venture Fellowship Program (now in its third cohort) that sources graduate-student talent and evaluates potential investments alongside the investment team; an advisory board of scientific luminaries including 2013 Nobel Laureate Michael Levitt, NAS members Vadim Gladyshev and Thomas Rando, longevity researcher Matt Kaeberlein, and AI-bio pioneer Alex Zhavoronkov; and a wholly-owned operating subsidiary, Founders Search Advisors (FSA), launched November 2025 to recruit executive talent for portfolio companies using equity-based compensation. The operating team spans three Managing Partners (Ilya Suharenko, Garri Zmudze, Sergey Jakimov) and additional Partners, Venture Partners, Principals, and a COO and CFO. Distribution and deal sourcing run through direct advisor/fellow networks, the 'Through the Longevity Lens' Substack newsletter, LinkedIn/X channels, industry events, and partnerships with sector bodies such as the Longevity Science Foundation and the Longevity Biotech Association.

LongeVC firmographics

Firmographics
Name
LongeVC
Legal name
LongeVC
Website
https://longevc.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
LongeVC is an early-stage venture capital firm headquartered in Washington D.C. that deploys Fund I and Fund II capital across therapeutics, diagnostics, and longevity infrastructure, supporting 40-plus portfolio biotech and longevity companies globally.
Ownership category
akta.pro rank

LongeVC industry classification

Industry
Product category
Venture Capital
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAC
Late-Stage Venture Capital (Series C+)

Keywords

  • Venture capital
  • Biotech investing
  • Longevity investing
  • Early-stage investment
  • Healthcare venture capital

Where LongeVC is headquartered

Location

Headquarters

HQ city
Washington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

LongeVC business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Investment Returns / Carry: As a venture capital firm, LongeVC generates returns through equity investments in early-stage biotech companies. Returns come from portfolio company exits via IPOs, acquisitions, or secondary sales. The firm manages Fund I and Fund II, investing across therapeutics, diagnostics and prevention, and longevity infrastructure.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

LongeVC product offering

Product offering

Core offering

LongeVC is an early-stage venture capital firm that deploys capital into biotech and longevity-focused companies through Fund I and Fund II, with focused investment pillars in Therapeutics, Diagnostics & Prevention, and Longevity Infrastructure. The firm curates an ecosystem of more than 40 portfolio companies and provides strategic guidance, talent acquisition support, and connections to a global network of thought leaders. Complementary offerings include a 6-month paid Venture Fellowship Program and the Founders Search Advisors executive search firm launched in November 2025.

Product overview

LongeVC is a venture capital platform operating as a single, unified investment offering rather than a modular software product. The firm provides venture capital investment services alongside complementary programs including a Venture Fellowship Program for talent development and Founders Search Advisors for executive recruiting. The core investment focus spans three verticals: Therapeutics (pre-clinical and clinical drug development targeting aging mechanisms), Diagnostics & Prevention (early-stage personalized medicine and advanced diagnostics), and Longevity Infrastructure (platform technologies enabling faster drug discovery and testing at scale).

Differentiator

Problem solved

Functional benefit

Brands

  • Founders Search Advisors (FSA): Executive search firm launched by LongeVC to assist longevity biotech startups in recruiting top talent using equity-based compensation model

Products and services

  • LongeVC Investment Platform (Fund I and Fund II) Early-stage venture capital investment platform operated through Fund I and Fund II that invests in exceptional biotech and longevity-focused founders developing therapeutics, diagnostics & prevention, and longevity infrastructure, providing capital alongside ecosystem connections to drive portfolio company advancement.
  • Venture Fellowship Program A 6-month, part-time, remote paid fellowship program for graduate students (MS/PhD) and postdoctoral fellows that provides paid exposure to biotech venture investing, including evaluating potential investments, participating in company pitches, and developing strategic initiatives in drug discovery, computational and synthetic biology, and genomic medicine.
  • Founders Search Advisors (FSA) Executive search firm launched by LongeVC to assist longevity biotech startups in recruiting top talent using an equity-based compensation model, addressing funding and talent acquisition challenges faced by early-stage longevity biotech companies.

Quantifiable outcome

  • Portfolio companies include industry leaders such as Insilico Medicine (AI drug discovery unicorn), Rubedo Life Sciences (senolytics), Turn.bio (mRNA medicines), and The Longevity Science Foundation (non-profit research funding)

Companies that use LongeVC

Customer profile

Segments2 records

Ideal customer profiles3 records

LongeVC technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

LongeVC partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Founders Search Advisors (FSA)coreStrategic or Co-development Partner · 6 November 2025Founders Search Advisors (FSA) is an executive search firm launched by LongeVC to assist longevity biotech startups in recruiting top talent using an equity-based compensation model. The firm addresses funding and talent acquisition challenges faced by early-stage longevity companies.
  • The Longevity Science FoundationcoreStrategic or Co-development PartnerThe Longevity Science Foundation is an international non-profit funding early-stage research on extending healthy human lifespan. LongeVC is connected to LSF through shared leadership (Alex Zhavoronkov serves on LSF's Visionary Board) and supports LSF's mission through investment and ecosystem building. LSF has launched campaigns such as the 'Invested in Her' crowdfunding for ovarian aging research.
  • Longevity Biotech AssociationcoreStrategic or Co-development PartnerThe Longevity Biotech Association is a portfolio organization and consortium aiming to advance the longevity industry by setting standards, educating stakeholders, and encouraging partnerships.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

LongeVC competitors and assessment

Company assessment

Broad incumbents

  • Andreessen Horowitz (a16z Bio): a16z Bio is the dedicated healthcare and biology investment arm of Andreessen Horowitz, investing in bio companies at the intersection of technology and life sciences. Comparable to LongeVC because of shared interest in AI-driven drug discovery and platform biotech, though a16z Bio operates with far greater resources.
  • 8VC: 8VC is a multi-stage venture firm with bio and longevity exposure alongside its broader tech portfolio. Comparable to LongeVC as an early-stage investor in biotech and life-sciences platforms, though 8VC operates across many technology categories beyond longevity.
  • Khosla Ventures: Khosla Ventures invests broadly across technology and biotech, including longevity-adjacent therapeutics and diagnostics. Comparable to LongeVC because both deploy early-stage capital into high-impact science, but Khosla operates at much greater AUM scale and across many sectors beyond biotech.
  • ARCH Venture Partners: ARCH Venture Partners is one of the largest dedicated biotech and advanced-technology venture firms, with deep exposure to longevity-relevant platforms. Comparable to LongeVC as a science-led biotech investor with Nobel-caliber scientific advisors, but at a substantially larger fund scale.
  • Founders Fund: Founders Fund invests across frontier technology sectors including biotech and longevity-adjacent companies. Comparable to LongeVC because both back bold science bets, but Founders Fund is a generalist tech investor with massive fund sizes compared to LongeVC's niche focus.

Regional players

  • Longevity Vision Fund: Longevity Vision Fund is a Russia-origin venture fund focused on longevity, biotech, and preventive medicine. Comparable to LongeVC as another dedicated longevity-focused VC, though it serves a different geographic ecosystem and overlaps with LongeVC in shared thesis on aging biology.

Direct peers

  • DCVC Bio: DCVC Bio is the dedicated bio and life sciences arm of DCVC, investing in early-stage biotech companies using computational and engineering approaches. Comparable to LongeVC because both target deep-tech biotech at the early stage and share an AI/bio convergence thesis.
  • Foresite Capital: Foresite Capital is a dedicated healthcare and biotech venture firm investing across therapeutics, diagnostics, and healthcare infrastructure. Comparable to LongeVC because both deploy capital into science-driven biotech and longevity infrastructure at the early stage.
  • Section 32: Section 32 is a venture capital firm that invests in biotech, healthtech, and technology platforms with a science-grounded approach. Directly comparable to LongeVC because both invest early in biotech and aim to back technical founders, though Section 32 is broader in scope beyond longevity.
  • Apollo Ventures: Apollo Ventures is a dedicated early-stage venture capital firm focused exclusively on longevity and age-related disease therapeutics. Highly comparable to LongeVC because it competes for the same small pool of longevity-focused biotech founders and shares a similar thesis-driven, science-led investment approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

LongeVC social profiles

Digital presence

LongeVC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LongeVC leadership team

Management profile

Number of profiles

Profiles28 records

LongeVC subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

LongeVC funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LongeVC M&A and investment

M&A and investment

M&A

Investments23 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LongeVC

What does LongeVC do?

LongeVC is an early-stage venture capital firm that deploys capital into biotech and longevity-focused companies through Fund I and Fund II, with focused investment pillars in Therapeutics, Diagnostics & Prevention, and Longevity Infrastructure. The firm curates an ecosystem of more than 40 portfolio companies and provides strategic guidance, talent acquisition support, and connections to a global network of thought leaders. Complementary offerings include a 6-month paid Venture Fellowship Program and the Founders Search Advisors executive search firm launched in November 2025.

Is LongeVC a public or private company?

LongeVC is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was LongeVC founded?

LongeVC was founded in 2020. It employs 11 to 50 people.

Where is LongeVC based?

LongeVC is headquartered in Washington, United States, in the North America region.

How does LongeVC make money?

One revenue line is on record: investment Returns / Carry.

Who are LongeVC's main competitors?

Broad incumbents on record are Andreessen Horowitz (a16z Bio), 8VC, Khosla Ventures, ARCH Venture Partners and Founders Fund. Longevity Vision Fund is listed as a regional player. Direct peers are DCVC Bio, Foresite Capital, Section 32 and Apollo Ventures.

Does LongeVC have an API?

No public API is recorded for LongeVC.

What industry is LongeVC in?

LongeVC's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAC, Late-Stage Venture Capital (Series C+). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyCan crowdfunding change ovarian aging research (and opinions)?The Longevity Science Foundation (LSF) has launched the "Invested in Her" crowdfunding campaign to raise $250,000 for ovarian aging and menopause research, with over $50,000 already secured and an additional $25,000 matching offer from LongeVC. The campaign focuses on three pillars: developing molecular sensors for tracking reproductive biomarkers, mapping biological mechanisms connecting ovarian aging to systemic decline, and exploring gene therapy and epigenetic reprogramming interventions. LSF CEO Joshua Herring argues that crowdfunding can build public engagement and pressure traditional funders to prioritize women's health research, an area historically underfunded despite affecting approximately half the global population.BioSpaceTrogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastomaTrogenix dosed the first patient in its Phase I/II ADePT trial of TGX-007, a dual-payload AAV gene therapy for glioblastoma, at UK and US sites. The trial will identify the optimal dose and evaluate safety and efficacy, with initial data expected to inform development across solid tumors.BioSpaceBeyond Buzzwords in Longevity InvestingThe article discusses a podcast episode featuring Sergey Jakimov and Artem Trotsyuk from LongeVC, focusing on strategies in longevity investing and drug development. The speakers emphasize concentrating on specific mechanisms that target age-related diseases rather than abstract aging goals.BioSpaceValidated Mechanisms, Strong Data Beat Hype in Longevity InvestingTwo investors from LongeVC discussed how longevity start-ups should focus on specific measurable disease targets rather than treating aging as a vague monolithic goal. They cited GLP-1 agonists as the first successful longevity product model, advising companies to generate solid clinical data, speak "FDA language," and follow a realistic path through classic biotech discipline to achieve commercial success. The investors also warned against chasing buzzword trends and emphasized the need for feasible timelines considering regulatory hurdles and business development cycles.FinSMEsValink Therapeutics Closes $11.8M Pre-A Financing RoundValink Therapeutics closed an $11.8M pre-A financing round led by redalpine, with participation from LongeVC, Oxford Science Enterprises, and existing investors. The funds will advance its pipeline of first-in-class bispecific antibody-drug conjugates for cancer, including two oncology programs in preclinical development for solid tumors.ValinktxPress Release: Valink Therapeutics Closes $11.8 Million Pre-A Financing Round to Advance Oncology PipelineValink Therapeutics Inc., a private biotechnology company developing bispecific antibody-drug conjugates for oncology, announced the closing of an $11.8 million Pre-A financing round on October 20, 2025. The funding was led by European venture capital firm redalpine, with participation from new investors LongeVC and Oxford Science Enterprises, as well as existing investors including RV Invest, Hoxton Ventures, and Oxonian Ventures. Proceeds will advance Valink's pipeline of first-in-class cancer treatments and support the company's expansion of its U.S. presence with headquarters in Cambridge, Massachusetts, alongside its R&D subsidiary in the United Kingdom.AxiosLongeVC's Sergey Jakimov raising $120M fundLongeVC is raising $120 million for its second fund to invest in early and mid-stage biotech and longevity-focused startups. Managing partner Sergey Jakimov sees major early-stage investment opportunities emerging in what has been characterized as the most difficult fundraising environment in years. The fund targets companies operating in the longevity and biotech sectors.Labs of LatviaLatvian LongeVC invests in US startup Glyphic BiotechnologiesLatvian fund LongeVC invested in US startup Glyphic Biotechnologies, which is developing a protein sequencing platform using single-molecule technology. The platform aims to overcome limitations of mass spectrometry, enabling better identification of biomarkers for early disease detection and tailored treatments.